Selective cross-tolerance to 5-HT1A and 5-HT2 receptor-mediated temperature and corticosterone responses.

Repeated administration of 5-MeODMT (3 mg/kg, twice daily for 14 days) in animals reduced the hypothermia and corticosterone secretion caused by an acute challenge with the 5-HT1A agonist 8-OH-DPAT, compared to vehicle-treated animals. Chronic 5-MeODMT did not affect hyperthermia or corticosterone secretion from the 5-HT2 agonist MK-212. Repeated administration of DOI (1 mg/kg daily for 7 days) reduced corticosterone but not body temperature increases from MK-212, and did not alter responses to 8-OH-DPAT. These results suggest that chronic 5-MeODMT selectively reduces 5-HT1A receptor-mediated responses, while chronic DOI selectively reduces 5-HT2 receptor-mediated corticosterone secretion without affecting thermoregulatory responses, supporting the independence of these receptor systems.

Study at a glance

Abstract

The repeated administration of 5-methoxy-N,N-dimethyltryptamine (5-MeODMT, 3 mg/kg, twice daily for 14 days) significantly diminished hypothermia and corticosterone secretion induced by an acute challenge with the 5-HT1A agonist 8-OH-DPAT (0.1 mg/kg) when compared to the responses in animals treated chronically with the solvent vehicle. In contrast, the chronic administration of 5-MeODMT did not alter the magnitude of hyperthermia or corticosterone secretion induced by the acute administration of MK-212 (1.0 mg/kg). The repeated administration of the 5-HT2 agonist DOI (1.0 mg/kg, daily for 7 days) significantly reduced the increase in corticosterone, but not body temperature, produced by MK-212. Chronic treatment with DOI did not alter the hypothermia or increase in corticosterone secretion elicited by 8-OH-DPAT. These data are consistent with other evidence that these physiological effects of 8-OH-DPAT and MK-212 are mediated by 5-HT1A and 5-HT2 receptors, respectively. Thus, data presented in these studies are suggestive that the chronic administration of 5-MeODMT diminishes the responsiveness of 5-HT1A receptor-mediated changes in body temperature and corticosterone secretion without altering the responses mediated by 5-HT2 receptors. In contrast, the chronic administration of DOI selectively diminishes the magnitude of 5-HT2 receptor-mediated changes in corticosterone secretion without affecting the responsiveness of those receptors involved in thermoregulatory responses. These selective changes in receptor responsiveness following the chronic administration of these 5-HT agonists further establishes the independence of 5-HT1A and 5-HT2 receptor-mediated pharmacological effects.